Disease‑Modifying Therapy for Ocular Surface Disease
While 17.8 million people have been diagnosed with Dry Eye Disease in the United States…
Fewer than 1 million (1 in 20) are currently treated with an FDA-approved product; presumably due to questionable efficacy and tolerability limitations.
Less than 5% (1 in 20) of Dry Eye Disease patients are currently treated with a FDA-approved product
Aramis Biosciences is a clinical-stage immuno‑ophthalmology biopharmaceutical company committed to the development of disease‑modifying therapy for ocular surface disease
Learn more about Aramis Biosciences
There are no upcoming events.